SEC Form 4 · accession 0001179110-18-002128
Theravance Biopharma, Inc. · TBPH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Shehnaaz Suliman
Officer — SVP, Corp Dev & Strategy
Period of report
Feb 12, 2018
Accepted (ET)
Feb 14, 2018 · 6:23 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001583107
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Feb 12, 2018 | A | 65,000 | $0.00 | A | 85,000 | D | |
| Ordinary SharesF1 | Feb 12, 2018 | A | 25,000 | $0.00 | A | 110,000 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1On August 1, 2017, the reporting person was granted a performance stock award that vests based on the achievement of certain performance conditions from August 1, 2017 through December 31, 2020 and continued employment. On February 12, 2018, the performance conditions applicable to 25,000 shares were deemed achieved and such shares will vest on February 20, 2018.